Focus: Radius Health is a publicly traded biotech company headquartered in Boston focused on endocrinology and oncology with both small molecule and biologic capabilities. The company is heavily dependent on its flagship osteoporosis drug TYMLOS, which generates 100% of revenue.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Radius Health to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Radius Health
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Radius Health's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Company's sole revenue driver representing 100% of commercial value; protects through 2040 but creates existential dependency risk.
Established bisphosphonate with minimal revenue contribution (<1% of company total) but approaching LOE in 2031.
Generic post-LOE asset with no material revenue or commercial significance.
1 discontinued, 0 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 3 crawl cycles
Source: USCIS H-1B Employer Data Hub